National Eye Institute

CompanyUnited StatesFounded 1968

ROROpenAlexWikidata

National Eye Institute develops 2 assets, the furthest in phase 3 (NT-501 in macular telangiectasia type 2). Mostly cell therapy; based in the United States, founded in 1968.

2
Assets
Furthest stage
Phase 3
66
Grants
66
Trials
53
Signals

Pipeline

2
  • NT-501

    Encapsulated engineered cells release ciliary neurotrophic factor to support retinal photoreceptor survival.

    Phase 3, Cell therapy, macular telangiectasia type 2, retinitis pigmentosa (Phase 2)

  • iPSC-derived RPE/PLGA transplantation

    Replaces damaged retinal pigment epithelium with autologous induced pluripotent stem cell-derived cells on a biodegradable scaffold.

    Phase 1, Cell therapy, dry age-related macular degeneration, geographic atrophy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials134
  • People11
  • Signals20
  • Similar companies6

Papers

Intelligence